Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis

Background: This article is based on our previous research, which was presented at the 2023 ASCO Annual Meeting I and published in Journal of Clinical Oncology as Conference Abstract (JCO. 2023;41:e16148. doi: 10.1200/JCO.2023.41.16_suppl.e16148). Both anti-programmed death 1/ligand-1 (PD-1/L1) anti...

全面介绍

Saved in:
书目详细资料
Main Authors: Yiwen Zhou (Author), Jingjing Li (Author), Jieer Ying (Author)
格式: 图书
出版: Open Exploration Publishing Inc., 2024-06-01T00:00:00Z.
主题:
在线阅读:Connect to this object online.
标签: 添加标签
没有标签, 成为第一个标记此记录!

因特网

Connect to this object online.

3rd Floor Main Library

持有资料详情 3rd Floor Main Library
索引号: A1234.567
复印件 1 可用